|
Título:
|
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria
|
|
Autores:
|
Llanos-Cuentas, Alejandro ;
Lacerda, Marcus V. G. ;
Hien, Tran T. ;
Velez, Ivan D. ;
Namaik-Larp, Chayadol ;
Chu, Cindy S. ;
Villegas, Maria F. ;
Val, Fernando ;
Monteiro, Wuelton M. ;
Brito, Marcelo A. M. ;
Costa, Monica R. F. ;
Chuquiyauri, Raúl ;
Casapía, Martin ;
Nguyen, Chau H. ;
Aruachan, Sandra ;
Papwijitsil, Ratchadaporn ;
Nosten, Francois H. ;
Bancone, Germana ;
Angus, Brian ;
Duparc, Stephan ;
Craig, Graham ;
Rousell, Victoria M. ;
Jones, Sion W. ;
Hardaker, Elizabeth ;
Clover, Donna D. ;
Kendall, Lindsay ;
Mohamed, Khadeeja ;
Koh, Gavin C. K. W. ;
Wilches, Viviana M. ;
Breton, John J. ;
Green, Justin A.
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Massachusetts Medical Society, 2019-07-04T17:01:20Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
BACKGROUND: Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed "radical cure." METHODS: We performed a phase 3, prospective, double-blind, double-dummy, randomized, controlled trial to compare tafenoquine with primaquine in terms of safety and efficacy. The trial was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and female patients with moderate G6PD enzyme deficiency; all patients had confirmed P. vivax parasitemia. The patients were randomly assigned, in a 2:1 ratio, to receive a single 300-mg dose of tafenoquine or 15 mg of primaquine once daily for 14 days (administered under supervision); all patients received a 3-day course of chloroquine and were followed for 180 days. The primary safety outcome was a protocol-defined decrease in the hemoglobin level (>3.0 g per deciliter or >/=30% from baseline or to a level of
|
|
En línea:
|
http://doi.org/10.1056/NEJMoa1802537
|
